Ernexa Therapeutics Inc. (ERNA) NASDAQ
8.00
-1.12(-12.28%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
8.00
-1.12(-12.28%)
Currency In USD
| Previous Close | 9.12 |
| Open | 9.08 |
| Day High | 9.08 |
| Day Low | 8 |
| 52-Week High | 75 |
| 52-Week Low | 3.18 |
| Volume | 53,401 |
| Average Volume | 1.62M |
| Market Cap | 2.51M |
| PE | 0.01 |
| EPS | 1,214.25 |
| Moving Average 50 Days | 6.98 |
| Moving Average 200 Days | 22.61 |
| Change | -1.12 |
Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series
GlobeNewswire Inc.
Feb 20, 2026 2:05 PM GMT
Live video webcast with Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics, on Wednesday, February 25th at 4:00 PM ET Register here CAMBRIDGE, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an
Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering
GlobeNewswire Inc.
Feb 06, 2026 2:25 PM GMT
CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics Inc. (Nasdaq: ERNA) (“Ernexa” or the “Company”), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announ
Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA
GlobeNewswire Inc.
Feb 03, 2026 1:45 PM GMT
Access the “What This Means” segment here CAMBRIDGE, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, tod